Gilead Sciences, Inc.

Anna Chiu

Olga Viktorovna Lapina

Brenda J Chan

Andrew S Thompson

Winston C Tse

Gregory Notte

Mark Andres

Ernest A Carra

Keshab Sarma

Valeriya N Smolenskaya

Lars V Heumann

Brandon Heath Brown

Troy Evan Reynolds

Stephen Paul Lathrop

Dana J Levine

Stephen R Yant

Brenda J Burke Chan

Lok Him Yu

Tao Wang

John Enquist

David Allen Siler

Norihiro Ikemoto

Zhihui Peng

Christopher Hale

Scott E Lazerwith

Dimitrios Stefanidis

Petinka I Vlahova

Tomas Cihlar

Katie Ann Keaton

Eric Gorman

Charles William Rowe

Andrew W Waltman

Nolan Griggs

John Enquist, Jr

Elena Bekerman

Andrew S Thomson

Matt Kraft

Michel Leeman

Wade S Blair

Jim X Zheng

Laura Elizabeth Bauer

Kate Schrier

Andrew Stephen Mulato

Martin Sunkwang Rhee

Jonathan Trinidad

Scott P Sellers

Jochem Van Herpt

Eric M Gorman

Valeriya Smolenskaya

Stephan P Lathrop

The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Capsid inhibitors for the treatment of HIV

The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.

Capsid inhibitors for the prevention of HIV

Methods of making compounds of Formula I are disclosed: 

Synthesis of polycyclic-carbamoylpyridone compounds

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Solid forms of an ASK1 inhibitor

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide(Compound I) were prepared and characterized in the solid state:  Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline solid forms of the selective late sodium current inhibitor 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Solid forms of an ion channel modulator

Growing community of inventors

Burlingame, CA, United States of America

Anna Chiu